As an overall conclusion, the above findings stress some potential of MMP-2 as a biomarker for monitoring PTSD severity, particularly in the early recovery phase (Past PTSD ≤5 y), where it is linked to overall symptom burden and arousal symptoms. This evidence concerns the gene MMP2 and post-traumatic stress disorder.